Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [7]. Core Views - The company is positioned at the bottom of the pesticide industry cycle, leveraging its integrated production chain based on phosgene to explore new opportunities [4]. - The overall pesticide prices are at a relatively low point, with expectations for recovery to enhance profitability [7]. - The company has a robust cash flow, which supports the upgrading of its industrial chain and optimizes costs [7]. Summary by Sections 1. Complete Industrial Chain Supports Rapid Development - The company is one of the largest domestic producers of pesticide raw materials and intermediates based on phosgene, forming a complete industrial chain from raw materials to intermediates to agricultural products [12]. - The company has a stable shareholding structure, with the actual controllers holding a high concentration of shares, which is beneficial for long-term development [17]. - The company has ample funds, with a total of 8.685 billion yuan in cash and other liquid assets by 2024, providing sufficient financial support for long-term construction and development [23]. 2. Steady Development of the Pesticide Sector - The pesticide sector is experiencing price recovery from a low point, which is expected to enhance profits [7]. - The company is a leading producer of the fungicides carbendazim and methyl thiophanate, with significant production capacity [32]. - The company is among the first in China to achieve production of the herbicide dicamba, holding a leading position in domestic production capacity [45]. 3. Leveraging Phosgene Resources for Industrial Chain Expansion - The company is a leader in the phosgene-based pesticide industry, with a high entry barrier for phosgene production [7]. - Phosgene resources are scarce, and the company has a diverse range of downstream products [7]. - Phosgene can be used to produce isocyanates, which have excellent performance in modified products, providing new directions for industrial development [7]. 4. Profit Forecast and Valuation - The company is expected to achieve total revenue of 50.21 billion yuan, 54.49 billion yuan, and 59.67 billion yuan from 2025 to 2027, with year-on-year growth rates of 8.15%, 8.52%, and 9.51% respectively [7]. - The net profit attributable to shareholders is projected to be 9.39 billion yuan, 11.18 billion yuan, and 12.26 billion yuan for the same period, with growth rates of 20.59%, 19.07%, and 9.62% respectively [7]. - The earnings per share (EPS) are expected to be 1.03 yuan, 1.23 yuan, and 1.35 yuan, corresponding to price-to-earnings (P/E) ratios of 11.17, 9.38, and 8.55 [7].

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of 14.4 CNY [1][6]. Core Views - The company is expected to benefit from a price turning point for its core product, Mancozeb, and is anticipated to see contributions from new products in the future [1][6]. - The agricultural pesticide industry is showing signs of recovery, with improved sales volumes and pricing expected in the coming periods [6][7]. Financial Summary - **Revenue Forecast**: - 2024A: 4,643 million CNY, -20.9% YoY - 2025E: 5,367 million CNY, +15.6% YoY - 2026E: 6,092 million CNY, +13.5% YoY - 2027E: 6,849 million CNY, +12.4% YoY [2][7] - **Net Profit Forecast**: - 2024A: 779 million CNY, -45.9% YoY - 2025E: 875 million CNY, +12.4% YoY - 2026E: 1,066 million CNY, +21.9% YoY - 2027E: 1,237 million CNY, +16.0% YoY [2][7] - **Earnings Per Share (EPS)**: - 2024A: 0.86 CNY - 2025E: 0.96 CNY - 2026E: 1.17 CNY - 2027E: 1.36 CNY [2][7] - **Valuation Ratios**: - Price-to-Earnings (P/E) ratio is projected to be 13, 11, 9, and 8 for 2024A, 2025E, 2026E, and 2027E respectively [2][7]. Market Performance - The company has experienced a significant decline of 34% over the past year, compared to the Shanghai Composite Index [5]. Product Insights - The company’s main pesticide raw materials saw a sales volume increase of 37.16% YoY in 2024, despite a price drop of 33.78% [6][7]. - The price of Mancozeb is expected to rise from 32,800 CNY/ton to 37,000 CNY/ton, indicating a positive trend for the company's performance [6][7]. Investment Recommendations - The company is positioned to leverage its integrated capabilities and cost advantages, with a strong return on equity (ROE) and significant cash reserves for capital expenditures [6][7]. - The adjusted profit expectations for 2025-2027 are 875 million CNY, 1,066 million CNY, and 1,237 million CNY respectively, with a corresponding P/E of 11, 9, and 8 [6][7].